Publicaciones en colaboración con investigadores/as de Tel Aviv University (14)

2024

  1. Comparison of assays measuring extracellular vesicle tissue factor in plasma samples: communication from the ISTH SSC Subcommittee on Vascular Biology

    Journal of Thrombosis and Haemostasis, Vol. 22, Núm. 10, pp. 2910-2921

  2. Venous thromboembolism characteristics and outcomes among RIETE patients tested and untested for inherited thrombophilia

    Blood Advances, Vol. 8, Núm. 18, pp. 4950-4959

2023

  1. Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents

    Blood, Vol. 141, Núm. 3, pp. 219-230

  2. Parsaclisib, a PI3Kδ inhibitor, in relapsed and refractory follicular lymphoma (CITADEL-203): a phase 2 study

    eClinicalMedicine, Vol. 63

  3. Venous thromboembolism characteristics, treatment and outcomes in young adults: findings from the Registro Informatizado de Enfermedad TromboEmbólica registry

    Journal of Thrombosis and Haemostasis, Vol. 21, Núm. 10, pp. 2811-2823

2022

  1. Comparison of the Effectiveness and Safety of the Oral Selective Inhibitor of Nuclear Export, Selinexor, in Diffuse Large B Cell Lymphoma Subtypes

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 22, Núm. 1, pp. 24-33

  2. EHA Guidelines on Management of Antithrombotic Treatments in Thrombocytopenic Patients With Cancer

    HemaSphere, Vol. 6, Núm. 8

  3. The Association between Patient Characteristics and the Efficacy and Safety of Selinexor in Diffuse Large B-Cell Lymphoma in the SADAL Study

    Cancers, Vol. 14, Núm. 3

2021

  1. Health-related quality of life and utility outcomes with selinexor in relapsed/refractory diffuse large B-cell lymphoma

    Future Oncology, Vol. 17, Núm. 11, pp. 1295-1310

  2. Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open-label Phase II study

    British Journal of Haematology, Vol. 192, Núm. 5, pp. 869-878

  3. Survival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL study

    Journal of Hematology and Oncology

2020

  1. Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial

    The Lancet Haematology, Vol. 7, Núm. 7, pp. e511-e522

2018

  1. Single cell dissection of plasma cell heterogeneity in symptomatic and asymptomatic myeloma

    Nature Medicine, Vol. 24, Núm. 12, pp. 1867-1876

2016

  1. International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment

    Journal of Clinical Oncology, Vol. 34, Núm. 13, pp. 1544-1557